Debra L. Dugger
About
In The Last Decade
Debra L. Dugger
23 papers receiving 4.2k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Molecular Biology 2.7k
- Oncology 1.7k
- Radiology, Nuclear Medicine and Imaging 1.3k
- Immunology 1.1k
- Cancer Research 415
Countries citing papers authored by Debra L. Dugger
This map shows the geographic impact of Debra L. Dugger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra L. Dugger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra L. Dugger more than expected).
Fields of papers citing papers by Debra L. Dugger
This network shows the impact of papers produced by Debra L. Dugger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra L. Dugger. The network helps show where Debra L. Dugger may publish in the future.
Co-authorship network of co-authors of Debra L. Dugger
This figure shows the co-authorship network connecting the top 25 collaborators of Debra L. Dugger. A scholar is included among the top collaborators of Debra L. Dugger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra L. Dugger. Debra L. Dugger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 0 | |
| 3 | 8 | |
| 4 | 5 | |
| 5 | 54 | |
| 6 | 107 | |
| 7 | 71 | |
| 8 | Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis breakdown → | 407 |
| 9 | 289 | |
| 10 | 54 | |
| 11 | 49 | |
| 12 | 307 | |
| 13 | 46 | |
| 14 | Activity of Protein Kinase RIPK3 Determines Whether Cells Die by Necroptosis or Apoptosis breakdown → | 531 |
| 15 | 214 | |
| 16 | 90 | |
| 17 | 473 | |
| 18 | Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate breakdown → | 1259 |
| 19 | Trastuzumab-MC-vc-PAB-MMAF: The effects of the Drug:Antibody Ratio (DAR) on efficacy, toxicity and pharmacokinetics. | 3 |
| 20 | 82 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.